(3-bromopropoxy)cyclopropane | 1418119-92-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (3-bromopropoxy)cyclopropane
• 英文别名: (3-Bromopropoxy)cyclopropane；3-bromopropoxycyclopropane
• CAS: 1418119-92-2
• 化学式: C₆H₁₁BrO
• 分子量: 179.057
• InChiKey: CRLOOAQXRHXDLI-UHFFFAOYSA-N

物化性质

• 沸点：
  168.0±13.0 °C(Predicted)
• 密度：
  1.38±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  8
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (3-bromopropoxy)cyclopropane 在 ammonium hydroxide 、 copper(l) iodide 、 potassium carbonate 、 caesium carbonate 、 L-脯氨酸 作用下， 以 二甲基亚砜 、 N,N-二甲基甲酰胺 为溶剂， 反应 10.0h， 生成 6-amino-1-(3-cyclopropoxypropyl)-3,3-dimethylindolin-2-one
  参考文献：
  名称：

  [EN] 2-OXO-2,3-DIHYDRO-INDOLES FOR THE TREATMENT OF CNS DISORDERS
  [FR] 2-OXO-2,3-DIHYDRO-INDOLES DESTINÉS AU TRAITEMENT DE TROUBLES DU SNC

  摘要：

  本发明涉及一般式(I)的2-氧代-2,3-二氢吲哚，其中（N1）是苯基或杂环芳基，选择自吡啶基、嘧啶基、咪唑基、异噁唑基或吡唑基；（N2）是苯基或吡啶基，其中吡啶基中的N原子可以在所有自由位置上；R1是氢、低碳基、被卤素取代的低碳基、低烷氧基或卤素；n为1或2；若n为2，则R1可以相同也可以不同；R2/R2'彼此独立地为低碳基，或与它们连接的碳原子一起形成一个C3-6环烷基环；R3是低碳基、C3-6环烷基、CH2-C3-6环烷基、C3-6环烷基其中一个环碳原子被-O-取代、（CH2）3-O-C3-6环烷基、被羟基取代的低碳基、被卤素取代的低碳基、（CH2）3-S(O)2-C3-6环烷基或（CH2）2-S(O)2-低碳基；R4是氢、卤素或低碳基；m为1或2；若m为2，则R4可以相同也可以不同；以及其药学上可接受的盐、消旋混合物、或其对应的对映体和/或光学异构体和/或立体异构体。

  公开号：

  WO2014040969A1
• 作为产物：
  描述：

  3-cyclopropoxypropan-1-ol 在 四溴化碳 、 三苯基膦 作用下， 以 正戊烷 为溶剂， 反应 18.0h， 生成 (3-bromopropoxy)cyclopropane
  参考文献：
  名称：

  [EN] 2-OXO-2,3-DIHYDRO-INDOLES FOR THE TREATMENT OF CNS DISORDERS
  [FR] 2-OXO-2,3-DIHYDRO-INDOLES DESTINÉS AU TRAITEMENT DE TROUBLES DU SNC

  摘要：

  本发明涉及一般式(I)的2-氧代-2,3-二氢吲哚，其中（N1）是苯基或杂环芳基，选择自吡啶基、嘧啶基、咪唑基、异噁唑基或吡唑基；（N2）是苯基或吡啶基，其中吡啶基中的N原子可以在所有自由位置上；R1是氢、低碳基、被卤素取代的低碳基、低烷氧基或卤素；n为1或2；若n为2，则R1可以相同也可以不同；R2/R2'彼此独立地为低碳基，或与它们连接的碳原子一起形成一个C3-6环烷基环；R3是低碳基、C3-6环烷基、CH2-C3-6环烷基、C3-6环烷基其中一个环碳原子被-O-取代、（CH2）3-O-C3-6环烷基、被羟基取代的低碳基、被卤素取代的低碳基、（CH2）3-S(O)2-C3-6环烷基或（CH2）2-S(O)2-低碳基；R4是氢、卤素或低碳基；m为1或2；若m为2，则R4可以相同也可以不同；以及其药学上可接受的盐、消旋混合物、或其对应的对映体和/或光学异构体和/或立体异构体。

  公开号：

  WO2014040969A1

文献信息

• [EN] INDOLIN-2-ONE OR PYRROLO-PYRIDIN/PYRIMIDIN-2-ONE DERIVATIVES<br/>[FR] DÉRIVÉS INDOLIN-2-ONE OU PYRROLO-PYRIDIN/PYRIMIDIN-2-ONE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2014202493A1

  公开（公告）日：2014-12-24

  The present invention is concerned with 2-oxo-2,3-dihydro-indoles of general formula (I) wherein Ar is a heteroaryl group, containing one, two or three heteroatoms, selected from N, S or O; R1 is hydrogen, lower alkyl, halogen, amino, dimethylamino, cyano, lower alkyl substituted by halogen, lower alkyl substituted by hydroxy, CH(OH)CF3, (CH2)o-lower alkoxy, cycloalkyl optionally substituted by CF3, or heterocycloalkyl optionally substituted by lower alkyl; R2 is hydrogen, lower alkyl, (CH2)o-cycloalkyl, (CH2)o-O-cycloalkyl, (CH2)o-lower alkoxy, CH2)o-lower alkoxy substituted by halogen, (CH2)o-heterocycloalkyl optionally substituted by lower alkyl, (CH2)o-S(O)2-cycloalkyl, lower alkyl substituted by one or two hydroxy, lower alkyl substituted by one or two lower alkoxy, (CH2)o-S(O)2-lower alkyl, lower alkyl substituted by halogen or CH2CH(OH)CF3; R3 is halogen or lower alkyl; X is CH or N; X1 is CH or N; n is 1 or 2; o is 0, 1, 2 or 3; m is 0, 1 or 2; and the dotted line is a bond or not; as well as with a pharmaceutically acceptable salts thereof, with a racemic mixture, or with its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof The compounds may be used for the treatment of certain central nervous system disorders which are positive (psychosis) and negative symptoms of schizophrenia, substance abuse, alcohol and drug addiction, obsessive-compulsive disorders, cognitive impairment, bipolar disorders, mood disorders, major depression, treatment resistant depression, anxiety disorders, Alzheimer's disease, autism, Parkinson's disease, chronic pain, borderline personality disorder, sleep disturbances, chronic fatigue syndrome, stiffness, antiinflammatory effects in arthritis and balance problems.

  本发明涉及通式（I）中的2-氧代-2,3-二氢吲哚，其中Ar是一个杂环烃基，含有一个、两个或三个杂原子，选自N、S或O；R1是氢、低碳基、卤素、氨基、二甲胺基、氰基、被卤素取代的低碳基、被羟基取代的低碳基、CH(OH)CF3、（CH2）o-低碳醚、环烷基（可选地被CF3取代）、或杂环烷基（可选地被低碳基取代）；R2是氢、低碳基、（CH2）o-环烷基、（CH2）o-O-环烷基、（CH2）o-低碳醚、被卤素取代的（CH2）o-低碳醚、（CH2）o-杂环烷基（可选地被低碳基取代）、（CH2）o-S(O)2-环烷基、被一个或两个羟基取代的低碳基、被一个或两个低碳醚取代的低碳基、（CH2）o-S(O)2-低碳基、被卤素或CH2CH(OH)CF3取代的低碳基；R3是卤素或低碳基；X是CH或N；X1是CH或N；n是1或2；o是0、1、2或3；m是0、1或2；虚线是键或非键；以及其在药学上可接受的盐、消旋混合物、或其相应的对映体和/或光学异构体和/或立体异构体。这些化合物可用于治疗某些中枢神经系统障碍，包括精神病（阳性和阴性症状）、精神分裂症、物质滥用、酒精和药物成瘾、强迫症、认知障碍、双相情感障碍、情绪障碍、重性抑郁症、治疗难治性抑郁症、焦虑障碍、阿尔茨海默病、自闭症、帕金森病、慢性疼痛、边缘人格障碍、睡眠障碍、慢性疲劳综合征、僵硬、关节炎的抗炎作用和平衡问题。
• 2-OXO-2,3-DIHYDRO-INDOLES FOR THE TREATMENT OF CNS DISORDERS
  申请人：Hoffmann-La Roche Inc.

  公开号：US20150284386A1

  公开（公告）日：2015-10-08

  The present invention is concerned with 2-oxo-2,3-dihydro-indoles of general formula wherein is phenyl or a heteroaryl group, selected from pyridinyl, pyrimidinyl, imidazolyl, isoxazolyl or pyrazolyl; is phenyl or pyridinyl, wherein the N atom in the pyridinyl group may be on all free positions; R 1 is hydrogen, lower alkyl, lower alkyl substituted by halogen, lower alkoxy or halogen; n is 1 or 2; if n is 2, R 1 may be the same or not; R 2 /R 2′ are independently from each other lower alkyl, or form together with the carbon atom to which they are attached a C 3-6 -cycloalkyl ring; R 3 is lower alkyl, C 3-6 -cycloalkyl, CH 2 —C 3-6 -cycloalkyl, C 3-6 -cycloalkyl wherein one ring-carbon atom is replaced by —O—, (CH 2 ) 3 —O—C 3-6 -cycloalkyl, lower alkyl substituted by hydroxy, lower alkyl substituted by halogen, (CH 2 ) 3 —S(O) 2 —C 3-6 -cycloalkyl or (CH 2 ) 2 —S(O) 2 -lower alkyl; R 4 is hydrogen, halogen or lower alkyl; m is 1 or 2; if m is 2, R 4 may be the same or not; as well as with a pharmaceutically acceptable salts thereof, with a racemic mixture, or with its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof.

  本发明涉及一般式的2-氧代-2,3-二氢吲哚： 其中 R1为氢、较低的烷基、被卤素取代的较低的烷基、较低的烷氧基或卤素； n为1或2；如果n为2，则R1可以相同也可以不同； R2/R2′互相独立，为较低的烷基，或与它们所附着的碳原子一起形成C3-6环烷基环； R3为较低的烷基、C3-6环烷基、CH2—C3-6环烷基、C3-6环烷基，其中一个环碳原子被—O—取代，(CH2)3—O—C3-6环烷基、被羟基取代的较低的烷基、被卤素取代的较低的烷基、(CH2)3—S(O)2—C3-6环烷基或(CH2)2—S(O)2-较低的烷基； R4为氢、卤素或较低的烷基； m为1或2；如果m为2，则R4可以相同也可以不同； 以及其药学上可接受的盐、其外消旋混合物、其对应的对映体和/或光学异构体和/或立体异构体。
• 2-oxo-2,3-dihydro-indoles for the treatment of CNS disorders
  申请人：Hoffmann-La Roche Inc.

  公开号：US09221816B2

  公开（公告）日：2015-12-29

  The present invention is concerned with 2-oxo-2,3-dihydro-indoles of general formula wherein is phenyl or a heteroaryl group, selected from pyridinyl, pyrimidinyl, imidazolyl, isoxazolyl or pyrazolyl; is phenyl or pyridinyl, wherein the N atom in the pyridinyl group may be on all free positions; R1 is hydrogen, lower alkyl, lower alkyl substituted by halogen, lower alkoxy or halogen; n is 1 or 2; if n is 2, R1 may be the same or not; R2/R2′ are independently from each other lower alkyl, or form together with the carbon atom to which they are attached a C3-6-cycloalkyl ring; R3 is lower alkyl, C3-6-cycloalkyl, CH2—C3-6-cycloalkyl, C3-6-cycloalkyl wherein one ring-carbon atom is replaced by —O—, (CH2)3—O—C3-6-cycloalkyl, lower alkyl substituted by hydroxy, lower alkyl substituted by halogen, (CH2)3—S(O)2—C3-6-cycloalkyl or (CH2)2—S(O)2-lower alkyl; R4 is hydrogen, halogen or lower alkyl; m is 1 or 2; if m is 2, R4 may be the same or not; as well as with a pharmaceutically acceptable salts thereof, with a racemic mixture, or with its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof.

  本发明涉及具有以下一般式的2-氧代-2,3-二氢吲哚：其中R1为氢，较低的烷基，被卤素取代的较低烷基，较低的烷氧基或卤素；n为1或2；如果n为2，则R1可以相同或不同；R2 / R2′独立地为较低的烷基，或与它们附着的碳原子一起形成C3-6环烷基环；R3为较低的烷基，C3-6环烷基，CH2-C3-6环烷基，C3-6环烷基，其中一个环碳原子被-O-替换，（CH2）3-O-C3-6环烷基，被羟基取代的较低烷基，被卤素取代的较低烷基，（CH2）3-S（O）2-C3-6环烷基或（CH2）2-S（O）2-较低烷基；R4为氢，卤素或较低的烷基；m为1或2；如果m为2，则R4可以相同或不同；以及其药学上可接受的盐，其外消旋混合物，或其对映体和/或光学异构体和/或立体异构体。
• INDOLIN-2-ONE OR PYRROLO-PYRIDIN/PYRIMIDIN-2-ONE DERIVATIVES
  申请人：Hoffmann-La Roche Inc.

  公开号：US20160095844A1

  公开（公告）日：2016-04-07

  The present invention is concerned with 2-oxo-2,3-dihydro-indoles of general formula wherein Ar is a 6-membered heteroaryl group, containing one or two N-atoms, which are the groups, pyridinyl, pyrimidinyl, pyridazinyl, or a 5-membered heteroaryl group containing from 1 to 3 heteroatoms, selected from N, S or O, which groups are imidazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadazolyl, isoxazolyl, oxazolyl, 1,3,4-thiadiazolyl or pyrazolyl; R 1 is hydrogen, lower alkyl, halogen, amino, dimethylamino, cyano, lower alkyl substituted by halogen, lower alkyl substituted by hydroxy, CH(OH)CF 3 , (CH 2 ) o -lower alkoxy, cycloalkyl optionally substituted by CF 3 , or heterocycloalkyl optionally substituted by lower alkyl; R 2 is hydrogen, lower alkyl, (CH 2 ) o -cycloalkyl, (CH 2 ) o —O-cycloalkyl, (CH 2 ) o -lower alkoxy, CH 2 ) o -lower alkoxy substituted by halogen, (CH 2 ) o -heterocycloalkyl optionally substituted by lower alkyl, (CH 2 ) o —S(O) 2 -cycloalkyl, lower alkyl substituted by one or two hydroxy, lower alkyl substituted by one or two lower alkoxy, (CH 2 ) o —S(O) 2 -lower alkyl, lower alkyl substituted by halogen or CH 2 CH(OH)CF 3 ; R 3 is halogen or lower alkyl; X is CH or N; X 1 is CH or N; n is 1 or 2; is 0, 1, 2 or 3; m is 0, 1 or 2; and the dotted line indicates a bond may or may not be present; or, a pharmaceutically acceptable salts thereof, with a racemic mixture, or with its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof The compounds may be used for the treatment of certain central nervous system disorders which are positive (psychosis) and negative symptoms of schizophrenia, substance abuse, alcohol and drug addiction, obsessive-compulsive disorders, cognitive impairment, bipolar disorders, mood disorders, major depression, treatment resistant depression, anxiety disorders, Alzheimer's disease, autism, Parkinson's disease, chronic pain, borderline personality disorder, sleep disturbances, chronic fatigue syndrome, stiffness, antiinflammatory effects in arthritis and balance problems.

  本发明涉及一般式为的2-氧代-2,3-二氢吲哚，其中Ar是6元杂环芳基基团，含有一个或两个N原子，该基团为吡啶基，嘧啶基，吡嗪基或含有1至3个杂原子的5元杂环芳基基团，所述杂原子选自N，S或O，该基团为咪唑基，1,2,4-噁二唑基，1,3,4-噁二唑基，异噁唑基，噁唑基，1,3,4-噻二唑基或吡唑基；R1为氢，低碳基，卤素，氨基，二甲氨基，氰基，低碳基取代的卤素，低碳基取代的羟基，CH（OH）CF3，（CH2）o-低碳基氧基，环烷基（可选）取代CF3或杂环烷基（可选）取代低碳基；R2为氢，低碳基，（CH2）o-环烷基，（CH2）o—O-环烷基，（CH2）o-低碳基氧基，（CH2）o-低碳基取代的卤素，（CH2）o-杂环烷基（可选）取代低碳基，（CH2）o—S（O）2-环烷基，低碳基取代1或2个羟基，低碳基取代1或2个低碳基氧基，（CH2）o—S（O）2-低碳基，低碳基取代卤素或CH2CH（OH）CF3；R3为卤素或低碳基；X为CH或N；X1为CH或N；n为1或2；为0,1,2或3；m为0,1或2；虚线表示可能存在或不存在键；或其药学上可接受的盐，与外消旋混合物或其对应的对映体和/或光学异构体和/或立体异构体一起使用。这些化合物可用于治疗某些中枢神经系统紊乱，包括精神病（阳性症状）和阴性症状的精神分裂症，物质滥用，酒精和药物成瘾，强迫症，认知障碍，双相障碍，情绪障碍，重度抑郁症，治疗难治性抑郁症，焦虑症，阿尔茨海默病，自闭症，帕金森病，慢性疼痛，边缘人格障碍，睡眠障碍，慢性疲劳综合症，僵硬，关节炎的抗炎作用和平衡问题的治疗。
• US9221816B2
  申请人：——

  公开号：US9221816B2

  公开（公告）日：2015-12-29